Recommendation of the President – Kanuma (sebelipaza alfa)
On 10 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation No. 66/20204 on the evaluation of the drug Kanuma (sebelipase alfa) under the drug program “Treatment of patients with lysosomal acid lipase deficiency (ICD-10 E75.5 E75.6)”